omeprazole has been researched along with dexlansoprazole in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (42.86) | 29.6817 |
| 2010's | 8 (38.10) | 24.3611 |
| 2020's | 4 (19.05) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bi, Y; Kuberan, B; Might, M; Vankayalapati, H | 1 |
| Chen, WL; Chen, X; Guo, XK; Jiang, ZY; Li, DD; Wang, YZ; Xu, JJ; You, QD | 1 |
| Cha, IJ; Hyun, MH; Kim, KA; Kim, MJ; Kim, MK; Park, JY; Shin, JG; Shon, JH; Yoon, YR; Yun, DH | 1 |
| Miura, M; Sugawara, K; Suzuki, T; Tada, H; Tateishi, T; Uno, T; Yasui-Furukori, N | 3 |
| Cha, IJ; Jung, WM; Kang, W; Kim, MJ; Liu, KH; Shin, JG | 1 |
| Cha, IJ; Kang, W; Kim, MJ; Liu, KH; Moon, YS; Seol, SY; Shin, JG; Shon, JH | 1 |
| Habuchi, T; Kagaya, H; Miura, M; Sagae, Y; Satoh, S; Suzuki, T; Tada, H | 1 |
| Kagaya, H; Miura, M; Suzuki, T; Tada, H; Tateishi, T; Uno, T; Yasui-Furukori, N | 1 |
| Miura, M | 1 |
| Bhatt, DL; Brooks, JK; Frelinger, AL; Lee, RD; Michelson, AD; Mulford, DJ; Nigam, A; Nudurupati, S; Wu, J | 1 |
| Chang, SY; Chen, C; Chimalakonda, A; Hurley, J; Rodrigues, AD; Thorndike, D; Vuppugalla, R; Wagner, A; Yang, Z; Zvyaga, T | 1 |
| Kim, EH; Kim, HY; Lee, SK; Park, CH; Roh, YH | 1 |
| Li, MJ; Li, Q; Liu, LQ; Sun, M | 1 |
| Karimova, MM; Makarenko, OV; Masheiko, AM; Onul, NM | 1 |
| Blaachandran, A; Ghoshal, UC; Misra, A; Rai, S | 1 |
| Lespessailles, E; Toumi, H | 1 |
| Barberio, B; Black, CJ; de Bortoli, N; Ford, AC; Savarino, E; Visaggi, P | 1 |
6 review(s) available for omeprazole and dexlansoprazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Enantioselective disposition of lansoprazole and rabeprazole in human plasma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexlansoprazole; Genotype; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Stereoisomerism | 2006 |
The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dexlansoprazole; Esomeprazole; Humans; Lansoprazole; Magnesium; Odds Ratio; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Risk Factors; Treatment Outcome | 2014 |
Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Comparative Effectiveness Research; Dexlansoprazole; Esomeprazole; Esophagitis, Peptic; Female; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Network Meta-Analysis; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome; United States; United States Food and Drug Administration | 2017 |
Proton Pump Inhibitors and Bone Health: An Update Narrative Review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Antacids; Bone Density; Dexlansoprazole; Esomeprazole; Humans; Lansoprazole; Omeprazole; Osteoporotic Fractures; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; United States | 2022 |
Comparison of acid-lowering drugs for endoscopy negative reflux disease: Systematic review and network Meta-Analysis.
Topics: Adult; Alginates; Dexlansoprazole; Endoscopy, Gastrointestinal; Gastroesophageal Reflux; Gastrointestinal Agents; Heartburn; Humans; Network Meta-Analysis; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2023 |
7 trial(s) available for omeprazole and dexlansoprazole
| Article | Year |
|---|---|
Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Algorithms; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Dexlansoprazole; Female; Half-Life; Humans; Korea; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Protein Binding; Reverse Transcriptase Polymerase Chain Reaction; Stereoisomerism | 2002 |
Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Dexlansoprazole; Female; Genotype; Half-Life; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Stereoisomerism; Time Factors | 2004 |
Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Dexlansoprazole; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Genotype; Heterozygote; Homozygote; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Stereoisomerism | 2005 |
Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Dexlansoprazole; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Female; Fluvoxamine; Genotype; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole | 2005 |
Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Dexlansoprazole; Humans; Immunosuppressive Agents; Kidney Transplantation; Kinetics; Lansoprazole; Mixed Function Oxygenases; Models, Molecular; Molecular Structure; Omeprazole; Rabeprazole; Stereoisomerism; Substrate Specificity; Tacrolimus | 2005 |
Intestinal CYP3A4 is not involved in the enantioselective disposition of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Beverages; Citrus paradisi; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexlansoprazole; Female; Humans; Intestines; Lansoprazole; Male; Metabolic Clearance Rate; Middle Aged; Omeprazole; Stereoisomerism | 2006 |
A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Area Under Curve; Blood Coagulation; Blood Platelets; Clopidogrel; Confidence Intervals; Cross-Over Studies; Dexlansoprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Reference Values; Ticlopidine; Young Adult | 2012 |
8 other study(ies) available for omeprazole and dexlansoprazole
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Repurposing of Proton Pump Inhibitors as first identified small molecule inhibitors of endo-β-N-acetylglucosaminidase (ENGase) for the treatment of NGLY1 deficiency, a rare genetic disease.
Topics: Dose-Response Relationship, Drug; Enzyme Inhibitors; Genetic Diseases, Inborn; Humans; Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase; Molecular Structure; Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase; Proton Pump Inhibitors; Proton Pumps; Rabeprazole; Small Molecule Libraries; Structure-Activity Relationship | 2017 |
Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Histone-Lysine N-Methyltransferase; Humans; Intracellular Signaling Peptides and Proteins; Leukemia; Molecular Structure; Myeloid-Lymphoid Leukemia Protein; Protein Binding; Proton Pump Inhibitors; Rabeprazole; Structure-Activity Relationship | 2020 |
Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Catalysis; Cytochrome P-450 CYP2C9; Dexlansoprazole; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Lansoprazole; Microsomes, Liver; Omeprazole; Stereoisomerism; Substrate Specificity | 2005 |
Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cells, Cultured; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dexlansoprazole; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Humans; Lansoprazole; Microsomes, Liver; Omeprazole; Stereoisomerism | 2005 |
Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cells, Cultured; Computer Simulation; Cytochrome P-450 CYP2C19; Dealkylation; Dexlansoprazole; Diazepam; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Hepatocytes; Humans; Kinetics; Lansoprazole; Liver; Microsomes, Liver; Models, Biological; NADP; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Recombinant Proteins; Substrate Specificity | 2012 |
Qualimetric analysis of proton pump inhibitors in Ukraine.
Topics: Dexlansoprazole; Esomeprazole; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Quality Control; Rabeprazole; Ukraine | 2019 |
Nocturnal acid breakthrough and esophageal acidification during treatment with dexlansoprazole as compared to omeprazole in patients with gastroesophageal reflux disease.
Topics: Dexlansoprazole; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Urease | 2022 |